The earnings call highlighted impressive revenue growth and significant advancements in clinical trials, suggesting a strong commercial outlook. However, these were tempered by supply chain challenges and ongoing patent litigation, leading to a mixed outlook.

Company Guidance -

Q3 2025

During the Corcept Therapeutics Second Quarter 2025 Earnings Conference Call, the company reported a second-quarter revenue of $194.4 million, up from $163.8 million in the same period last year, and adjusted their full-year 2025 revenue guidance to $850 million to $900 million. Net income was $35.1 million, slightly down from $35.5 million the previous year. Despite a record number of new prescribers and prescriptions, revenue growth was constrained by pharmacy vendor capacity issues, with a $15 million impact. Cash and investments totaled $515 million as of June 30, reflecting a $115 million stock repurchase. The company anticipates further growth, forecasting relacorilant to generate $3 billion to $5 billion annually in hypercortisolism revenue, and plans to expand their sales force from 145 to 175 clinical specialists by year-end.

Record Revenue Growth

Corcept Therapeutics reported a revenue of $194.4 million for Q2 2025, a significant increase from $163.8 million in the prior year period, despite certain challenges.

Strong Endocrinology Division Performance

The endocrinology division saw a record number of new prescribers and prescriptions for the sixth consecutive quarter, with a 49% increase in tablets shipped compared to the previous year.

Positive CATALYST Study Outcomes

The CATALYST study showed that 1 in 4 patients with difficult-to-control diabetes have hypercortisolism, and treatment with a cortisol modulator improved their signs and symptoms significantly.

Promising ROSELLA Trial Results

The ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, with a 30% reduction in the risk of disease progression.

Expansion of Sales Force

The company significantly increased its sales force to 145 clinical specialists, with plans to reach 175 by the end of the year, to support growing demand.

Corcept Therapeutics (CORT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CORT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.17 / -	0.41	―	―	―
Jul 31, 2025	2025 (Q2)	0.19 / 0.29	0.32	-9.38% (-0.03)	―
May 05, 2025	2025 (Q1)	0.14 / 0.17	0.25	-32.00% (-0.08)
Feb 26, 2025	2024 (Q4)	0.43 / 0.26	0.28	-7.14% (-0.02)	―
Oct 30, 2024	2024 (Q3)	0.28 / 0.41	0.28	46.43% (+0.13)	―
Jul 29, 2024	2024 (Q2)	0.23 / 0.32	0.25	28.00% (+0.07)	―
May 01, 2024	2024 (Q1)	0.22 / 0.25	0.14	78.57% (+0.11)	―
Feb 15, 2024	2023 (Q4)	0.26 / 0.28	0.14	100.00% (+0.14)	―
Nov 01, 2023	2023 (Q3)	0.22 / 0.28	0.3	-6.67% (-0.02)	―
Aug 02, 2023	2023 (Q2)	0.15 / 0.25	0.24	4.17% (+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CORT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$67.17	$69.00	+2.72%
May 05, 2025	$73.94	$70.74	-4.33%
Feb 26, 2025	$63.37	$59.85	-5.55%
Oct 30, 2024	$46.89	$48.97	+4.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Corcept Therapeutics (CORT) report earnings?

Corcept Therapeutics (CORT) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).

What is Corcept Therapeutics (CORT) earnings time?

Corcept Therapeutics (CORT) earnings time is at Oct 29, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CORT EPS forecast?

CORT EPS forecast for the fiscal quarter 2025 (Q3) is 0.17.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing